Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 02:45PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-6.16 Insider Own26.96% Shs Outstand29.93M Perf Week2.75%
Market Cap95.02M Forward P/E- EPS next Y-2.13 Insider Trans-0.11% Shs Float24.56M Perf Month-0.16%
Income-179.05M PEG- EPS next Q-0.70 Inst Own28.05% Short Float10.14% Perf Quarter8.26%
Sales1.38M P/S68.86 EPS this Y58.67% Inst Trans-5.10% Short Ratio1.62 Perf Half Y9.10%
Book/sh-1.89 P/B- EPS next Y16.39% ROA-128.10% Short Interest2.49M Perf Year-86.64%
Cash/sh1.94 P/C1.46 EPS next 5Y- ROE-1766.94% 52W Range1.91 - 29.56 Perf YTD-4.22%
Dividend Est.- P/FCF- EPS past 5Y-35.97% ROI-402.10% 52W High-90.44% Beta0.40
Dividend TTM- Quick Ratio2.57 Sales past 5Y53.60% Gross Margin-19.64% 52W Low47.94% ATR (14)0.20
Dividend Ex-Date- Current Ratio2.65 EPS Y/Y TTM-4.12% Oper. Margin-12053.26% RSI (14)52.43 Volatility7.09% 6.28%
Employees74 Debt/Eq- Sales Y/Y TTM268.00% Profit Margin-12974.86% Recom1.80 Target Price6.30
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q61.29% Payout- Rel Volume0.24 Prev Close2.75
Sales Surprise-49.39% EPS Surprise17.09% Sales Q/Q57.98% EarningsMar 12 BMO Avg Volume1.54M Price2.83
SMA203.67% SMA50-2.15% SMA200-31.08% Trades Volume303,085 Change2.75%
Date Action Analyst Rating Change Price Target Change
Feb-21-24Downgrade UBS Buy → Neutral $9 → $4
Aug-15-23Downgrade Mizuho Buy → Neutral $40 → $4
Jul-17-23Downgrade Guggenheim Buy → Neutral
Mar-10-23Downgrade Jefferies Buy → Hold $20 → $22
Dec-01-22Upgrade Goldman Sell → Neutral $16
Jul-07-22Initiated Mizuho Buy $19
Apr-06-22Reiterated BofA Securities Buy $80
Nov-15-21Downgrade Goldman Neutral → Sell $55 → $24
Apr-09-21Initiated Berenberg Buy $75
Feb-01-21Initiated UBS Buy $99
Today 07:00AM
Apr-10-24 07:00AM
Mar-25-24 07:00AM
Mar-15-24 07:00AM
Mar-13-24 08:57AM
09:48PM Loading…
Mar-12-24 09:48PM
Mar-07-24 02:52PM
Mar-01-24 07:00AM
Feb-22-24 12:58PM
Feb-14-24 08:30AM
Feb-13-24 09:00AM
Feb-12-24 07:14AM
Feb-09-24 09:05AM
Feb-08-24 04:01PM
07:00AM Loading…
Feb-06-24 07:00AM
Feb-05-24 07:00AM
Dec-12-23 07:00AM
Dec-11-23 07:00AM
Dec-01-23 07:29PM
Nov-30-23 07:00AM
Nov-24-23 06:40AM
Nov-15-23 02:23PM
Nov-14-23 07:52AM
Nov-08-23 07:00AM
Nov-06-23 07:00AM
Oct-31-23 07:00AM
Oct-30-23 07:00AM
09:18AM Loading…
Oct-25-23 09:18AM
Oct-17-23 10:26AM
Oct-10-23 09:45AM
Oct-04-23 07:00AM
Sep-28-23 05:35PM
Aug-29-23 07:30AM
Aug-17-23 10:30AM
Aug-15-23 05:43PM
Aug-14-23 11:04PM
Jul-31-23 07:00AM
Jul-07-23 08:16AM
Jul-05-23 10:20AM
Jun-29-23 04:12PM
Jun-15-23 09:46PM
Jun-02-23 06:20AM
Jun-01-23 07:00AM
May-25-23 04:03PM
May-16-23 07:00AM
May-11-23 03:13PM
May-09-23 02:03AM
May-08-23 04:54PM
May-04-23 08:00AM
May-02-23 07:00AM
Apr-24-23 07:00AM
Mar-22-23 08:21AM
Mar-14-23 04:15PM
Mar-11-23 09:25AM
Mar-10-23 02:32AM
Mar-09-23 07:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Feb-14-23 09:50AM
Feb-13-23 05:00PM
Feb-08-23 02:27PM
Jan-27-23 07:00AM
Jan-11-23 07:00AM
Dec-27-22 07:34AM
Dec-22-22 07:00AM
Dec-19-22 07:00AM
Dec-15-22 04:45PM
Dec-06-22 09:53AM
Dec-02-22 06:02PM
Dec-01-22 07:00AM
Nov-30-22 07:00AM
Nov-20-22 09:45AM
Nov-14-22 07:00AM
Nov-10-22 07:00AM
Oct-27-22 07:00AM
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehta VimalCEO and PresidentApr 04 '24Sale2.625,26813,82343,564Apr 08 07:32 PM
Steinhart Richard IChief Financial OfficerApr 04 '24Sale2.631,0692,8174,765Apr 08 07:32 PM
Yocca FrankChief Scientific OfficerApr 04 '24Sale2.631,0672,81212,763Apr 08 07:30 PM
Rodriguez JavierSee RemarksApr 04 '24Sale2.641,0122,6677,672Apr 08 07:30 PM
Wiley Matthew T.CHIEF COMMERCIAL OFFICERApr 04 '24Sale2.641,0082,6562,992Apr 08 07:31 PM
O'Neill VincentSee RemarksApr 04 '24Sale2.621654325,408Apr 08 07:32 PM
Mehta VimalCEO and PresidentJun 16 '23Option Exercise0.4130,00012,30069,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 16 '23Sale20.1830,000605,50139,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 15 '23Option Exercise0.4130,00012,30069,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 15 '23Sale21.5430,000646,22639,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentMay 22 '23Sale25.796,500167,64137,294May 24 04:37 PM
Steinhart Richard IChief Financial OfficerMay 15 '23Sale27.175,000135,8641,500May 16 08:32 PM
Rodriguez JavierSee RemarksMay 15 '23Sale27.321,78548,7654,350May 16 08:29 PM